



HEALTHCARE

Innovations in CNS

Novel therapeutics and future R&D strategies

By Michael F. O'Neill and Robert A McArthur

 [Table of Contents](#)

Michael F O'Neill

Dr O'Neill has over twenty years experience in academic and industrial research including time in management in major pharmaceutical companies such as Merck & Co and Eli Lilly. Dr O'Neill is now an advisor on drug development practice and strategy to the pharmaceutical and biotechnology industries with a special interest in CNS products. Michael founded Eolas Biosciences to help companies find efficient ways to progress innovative compounds through preclinical and clinical development. He advises investors and licensing professionals on opportunities and portfolio development strategy. Michael's consultancy has also expanded to include corporate coaching and organisational development.

Robert A McArthur

Dr McArthur has held senior research positions in major pharmaceutical companies including SmithKline Beecham, Pharmacia and Pharmacia and Upjohn for nearly twenty years before deciding to work full-time as a consultant on CNS drug discovery and development to the pharmaceutical and biotechnology industries, and to providers of venture capital. He has been actively involved in developing compounds for CNS indications such as reboxetine for major depressive disorders, cabergoline for Parkinson's and nicergoline for multi-infarct dementia and Alzheimer's. His present interests are in the role of animal models in the development of pharmaceuticals for behavioural disorders and translational initiatives associating effects observed in preclinical studies to the clinical situation.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Innovations in CNS

Executive Summary 12

Current market landscape & dynamics	12
Major depressive disorder	13
Anxiety disorders	14
Schizophrenia	15
Sleep disorders	16
Alzheimer's disease and other dementias	17
Movement disorders	18
Epilepsy	19
Pain	20
Pipeline analysis: paradigm shift and incremental innovation	21

Chapter 1 Current market landscape & dynamics 24

Summary	24
Introduction	25
Patient potential	26
The current CNS market	28
CNS sales by disease and top 5 brands per disease category	28
CNS sales by drug class	33
CNS sales by country	34
Top CNS companies	35
Top CNS brands	36
Unmet needs	38
Psychiatric disorders	39
Depression	40
Anxiety	41
Schizophrenia	41
Sleep disorders	42

Neurologic disorders	42
Alzheimer's	43
Epilepsy	43
Movement disorders	44
Pain	44
Innovations in CNS	45

Chapter 2 Major depressive disorder 50

Summary	50
Introduction	51
Epidemiology and economic burden	51
Current drug treatments	52
Limitations	54
Key unmet needs	55
Novel treatments for major depressive disorder	56
Directly acting serotonergic receptor agonists	58
Specific noradrenaline reuptake inhibitors (NARI)	58
Serotonin/noradrenaline reuptake inhibitors (SSNRI) and mixed, multiple reuptake inhibitors (MMRI)	59
Multi-target strategies	60
Neuropeptides and stress	61
Neurokinins	61
CRF-1	62
Others	62
Future directions	63
Conclusions	64

Chapter 3 Anxiety disorders 66

Summary	66
Introduction	67
Epidemiology and economic burden	68
Current drug treatments	69
Limitations	70
Key unmet needs	70
Novel treatments for anxiety disorders	70
GABA-A positive modulators	73
5-HT _{1A} receptor agonists	73
β -3-adrenoceptor agonists	74
NK-1 and CRF-1 receptor antagonists	75
AVP V _{1b} antagonists	75

Cholecystokinin-2 (CCK-2) receptor antagonists	75
Fatty acid amide hydrolase (FAAH) inhibitors	76
Metabotropic glutamate 3 (mGlu3) receptor agonists and mGlu5 receptor antagonists	76
Vomeropherins	77
Future directions	77
Conclusions	78

Chapter 4 Schizophrenia 80

Summary	80
Introduction	81
Epidemiology and economic burden	82
Current drug treatments	83
Limitations	86
Key unmet needs	86
Novel treatments for schizophrenia	87
Monoaminergic systems	90
Dopamine	90
5-HT _{2A} receptor antagonists and inverse agonists	93
Combined monoamine receptor antagonists	94
D ₂ /5-HT _{2A}	94
D ₂ /5-HT _{1A}	94
Non-monoaminergic strategies	96
Glutamate	96
Cholinergics	97
Neuropeptides	98
Future directions	99
Conclusions	100

Chapter 5 Sleep disorders 104

Summary	104
Introduction	105
Epidemiology and economic burden	105
Current drug treatments	106
Limitations	108
Key unmet needs	109
Novel treatments for sleep disorders	109
GABA-ergic treatments	110
Serotonergic treatments	111

Others	111
Future directions	112
Conclusions	112
Chapter 6	Alzheimer's disease & other dementias
	116
Summary	116
Introduction	117
Epidemiology and economic burden	117
Current drug treatments	118
Acetylcholinesterase inhibitors	121
NMDA antagonists	122
Limitations	123
Key unmet needs	123
Novel treatments for Alzheimer's disease	124
Symptomatic treatments	124
Cholinergic mechanisms	125
Glutamatergic mechanisms	127
Serotonergic mechanisms	129
Other mechanisms	130
Disease process modifiers	131
Amyloid cascade based treatments	132
Neuroinflammatory approaches	138
Neurotrophic factor approaches	139
Future directions	139
Conclusions	141
Chapter 7	Movement disorders
	144
Summary	144
Introduction	145
Parkinson's disease	145
Epidemiology and economic burden	145
Current drug treatments	146
Limitations	148
Key unmet needs	148
Novel treatments for Parkinson's disease	149
Adenosine A2A receptor antagonists	151
Stem cell and gene therapy for the dopaminergic system	151
Disease modifying strategies for PD	152

Limitations	185
Key unmet needs	185
Novel treatments for pain disorders	186
Pain	186
NMDA receptor antagonists	188
Cannabinoids	188
Calcium channel modulators	188
Nicotinic receptor agonists	189
Mu opiate receptor agonists	189
Delta opiates	190
Migraine	191
Triptans and NSAIDs	192
Non-serotonergic treatments	192
Calcitonin Gene Related Peptide (CGRP)	193
Gap junction blockers	193
Vanilloids	193
Ion channel blockers	194
Other novel mechanisms	194
Conclusions	194

Chapter 10 Pipeline analysis: paradigm shift and incremental innovation 198

Summary	198
Introduction	199
Risk and innovation: not a straight choice	199
Sanofi-Aventis	199
Pfizer	201
AstraZeneca	203
GlaxoSmithKline	203
Merck & Co.	205
Building on the value of the pipeline	206
Conclusions	207
Limited impact of the genomics revolution	207
The problem of diagnosis	208
Away from the blockbuster model: smaller markets, smaller indications, and the place of smaller companies	208

Chapter 11 Appendix 214

Reference	214
Index	223

List of Figures

Figure 1.1:	Evaluation of current treatment options for CNS indications	39
Figure 2.2:	Competitive dynamics of drug classes and leading brands in the depression market, 2005	53
Figure 4.3:	Competitive dynamics of drug classes and leading brands in the schizophrenia market, 2005	85
Figure 6.4:	Competitive dynamics of drug classes and leading brands in the Alzheimer's disease market, 2005	120
Figure 7.5:	Competitive dynamics of leading brands in the Parkinson's disease market, 2005	147
Figure 8.6:	Competitive dynamics of drug classes and leading brands in the epilepsy market, 2005	170

List of Tables

Table 1.1:	Prevalence of CNS disorders in the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK), 2005	26
Table 1.2:	Global CNS market sales by disease category, 2004-05	28
Table 1.3:	Top 5 brands in each disease category, 2005	29
Table 1.4:	Global CNS market sales by drug class, 2004-05	33
Table 1.5:	CNS drug sales by country, 2005	34
Table 1.6:	Top 20 companies in the CNS market by sales, 2005	35
Table 1.7:	Top 20 global CNS brands, 2005	37
Table 1.8:	Medicinal chemical properties of a successful CNS drug	47
Table 2.9:	Present development status of potential antidepressants, 2006	57
Table 3.10:	Present development status of potential anxiolytics – Phase II and III, 2006	71
Table 3.11:	Present development status of potential anxiolytics – Phase I and Preclinical, 2006	72
Table 4.12:	Present development status of potential antipsychotics, 2006	89
Table 5.13:	Drugs currently in use for the treatment of insomnia, 2006	107
Table 5.14:	Present development status of potential hypnotics, 2006	110
Table 6.15:	Present development status of potential symptomatic treatments for Alzheimer's disease, 2006	125
Table 6.16:	Present development status of potential disease modifying treatments for Alzheimer's disease, 2006	131
Table 7.17:	Present development status of potential treatments for Parkinson's disease, 2006	150
Table 7.18:	Present development status of potential treatments for motor neuron disease/ALS, 2006	156
Table 7.19:	Present development status of potential treatments for Huntington's disease, 2006	161
Table 8.20:	Present development status of potential novel anti-epileptic drugs, 2006	173
Table 9.21:	Side effects limiting the pharmacological treatment of pain with present pharmaceuticals	185
Table 9.22:	Present development status of potential treatments for pain disorders, 2006	187

Table 9.23:	Present development status of potential treatments for migraine disorders, 2006	191
Table 10.24:	Sanofi-Aventis' CNS pipeline, 2006	200
Table 10.25:	Pfizer's CNS pipeline, 2006	202
Table 10.26:	AstraZeneca's CNS pipeline, 2006	203
Table 10.27:	GlaxoSmithKline CNS pipeline, 2006	204
Table 10.28:	Merck & Co.'s CNS pipeline, 2006	205